INTRODUCTION {#s1}
============

Rare genetic disorders, particularly in developing countries, are frequently misdiagnosed because of the lack of adequate medical facilities and genetic diagnosis. Consequently, many of these cases present with fatal and progressed phenotypes, showing an unbiased natural history without intervention unlike those cases diagnosed in more developed countries ([@ALAWBATHANIMCS002139C16]; [@ALAWBATHANIMCS002139C18]).

Progressive pseudorheumatoid dysplasia (PPD; MIM 208230) primarily affects the articular cartilage and follows an autosomal recessive mode of inheritance. WNT1 inducible signaling pathway protein 3 (*WISP3),* the gene mutated in PPD, is located on Chromosome 6q22. It has five coding exons that encode a 354-amino acid protein. The protein is essential for skeletal growth and cartilage homeostasis, as it contributes to the regulation of type II collagen and aggrecan in chondrocytes ([@ALAWBATHANIMCS002139C19]).

The current family was recruited from a remote area in Yemen during an outreach genetic clinic. Although the index cases had their first symptoms 20 years ago, they did not receive the right diagnosis or treatment. Here, we show that PPD can evolve as a severe destructive and disabling disease unless proper treatment and rehabilitation are received.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

Our male case P1 is a 24-yr-old male born to consanguineous Yemeni parents. He was healthy at birth, and as a toddler, he achieved developmental milestones at normal age. By the age of 3, he started to have difficulties during walking and developed progressive knee deformities. Over several years, he developed progressive symmetric joint pain, stiffness, and swelling. The first joints involved were the knees, followed by hips, elbows, and hand joints. The pain involved almost all joints but was most severe in the hips and lower back.

The patient took nonsteroidal anti-inflammatory drugs (NSAIDs) whenever needed for severe pain but has never been on steroid therapy. There were no symptoms of numbness or tingling in the extremities and there were no problems in passing urine. At our exam, he exhibited a flexed posture in the trunk and extremities and abnormal gait ([Fig. 1](#ALAWBATHANIMCS002139F1){ref-type="fig"}A). We found enlargement of joints, which were more prominent in the interphalangeal, elbow, and knee joints ([Fig. 1](#ALAWBATHANIMCS002139F1){ref-type="fig"}A,B), but there were no signs of inflammation such as tenderness or redness. The range of movement of all joints was extremely restricted, including neck, spine, shoulder, elbow, wrist, knee, ankle, and interphalangeal joints of hands and feet (see [Supplemental Video 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002139/-/DC1)). His mental status, vision, hearing, and speech were normal.

![Clinical photos and radiologic images of the patient. (*A*) Enlargement of elbows, widening of the thoracic wall, and severe contractures of the fingers are visible. Note that the posture of the patient is altered because of severe joint involvement. (*B*) X-ray analysis of the whole body. Increased anteroposterior diameter of thoracic wall, platyspondyly, and irregularity of end plates. An anteroposterior radiograph of the hips showed narrowing of joint spaces and mild sclerotic and cystic changes on the acetabulum and the head of the femur. A hand radiograph demonstrated severe enlargement and cystic changes on proximal interphalangeal (PIP), distal interphalangeal (DIP), and metacarpophalangeal (MCP) joints and carpal bones and metaphyseal cupping of the radius and ulna. Foot and ankle radiographs also showed severe enlargement and cystic changes of tarsal and metatarsal joints. A bilateral knee radiograph revealed narrowing of joint spaces and secondary osteoporosis.](AlawbathaniMCS002139_F1){#ALAWBATHANIMCS002139F1}

From the family history, two siblings (sister P2 and brother; 22 and 20 yr old, respectively) were affected with a similar manifestation, and three granduncles were reported, who died between the ages of 60 and 70 with a history of the same complaints ([Fig. 2](#ALAWBATHANIMCS002139F2){ref-type="fig"}A). Although the disease is severe and disabling, it is mainly limited to the joints and does not affect other vital body organs, such as heart, liver, or brain and, consequently, life expectancy seems not to be reduced. In our studied family, the grandparents died between the ages of 60 and 70 yr and this is close to the average life expectancy in Yemen (estimated 65.5 yr according to WHO 2015; <http://www.who.int/countries/yem/en/>).

![Family pedigree and Sanger sequencing chromatograph. (*A*) The pedigree of a Yemeni family with PPD showing the consanguinity; the arrow indicates the index case P1. Case P2 underwent exome sequencing. (*B*) Sanger sequencing chromatograph confirming the mutation detected by Mendeliome (c: 868_869delAG, p.S290Lfs\*12). This mutation has been reported in compound heterozygosity with another missense mutation in one Italian family ([@ALAWBATHANIMCS002139C7]).](AlawbathaniMCS002139_F2){#ALAWBATHANIMCS002139F2}

Radiologic Analysis {#s2b}
-------------------

X-ray analysis was performed to thoracolumbar spine, hips, ankles, knees, wrists, and fingers. A lateral radiograph of the thoracolumbar spine showed an increase in anteroposterior diameter of the thoracic wall, platyspondyly, and irregularity of end plates. An anteroposterior radiograph of the hips showed narrowing of joint spaces and mild sclerotic and cystic changes on the acetabulum and the head of the femur. A hand radiograph revealed severe enlargement and cystic changes on proximal interphalangeal (PIP), distal interphalangeal (DIP), metacarpophalangeal (MCP) joints and carpal bones and metaphyseal cupping of the radius and ulna. Foot and ankle radiographs also showed severe enlargement and cystic changes in tarsal and metatarsal joints. A radiograph of the bilateral knees revealed narrowing of joint spaces and secondary osteoporosis ([Fig. 1](#ALAWBATHANIMCS002139F1){ref-type="fig"}B).

Genomic Analyses {#s2c}
----------------

To uncover the underlying genetic defect, we have performed targeted next-generation sequencing using a comprehensive gene panel for Mendelian diseases. This panel is offered by Illumina under the trade name TruSight One and has been referred to as Mendeliome by several groups throughout the world ([@ALAWBATHANIMCS002139C31]; [@ALAWBATHANIMCS002139C27]; [@ALAWBATHANIMCS002139C29]; [@ALAWBATHANIMCS002139C28]; [@ALAWBATHANIMCS002139C32]).

We filtered the variants for homozygous recessive inheritance as predicted by the pedigree ([Fig. 2](#ALAWBATHANIMCS002139F2){ref-type="fig"}A). The homozygous filtering showed a hit with a homozygous frameshift mutation in *WISP3* (*WNT1* inducible signaling pathway protein 3; NM_003880.3) in exon 5; c.868_869delAG, p.Ser290Leufs\*12 ([Table 1](#ALAWBATHANIMCS002139TB1){ref-type="table"}). Sanger sequencing was performed to confirm the mutation as well as the segregation of the mutation within the family ([Fig. 2](#ALAWBATHANIMCS002139F2){ref-type="fig"}B).

###### 

*WISP3* variant

  Chr:position GRCh37(hg19)   NCBI reference sequence   HGVS cDNA        HGVS protein        Variant type   Genotype
  --------------------------- ------------------------- ---------------- ------------------- -------------- ------------
  6:112390624-112390625       NM_003880.3               c.868_869delAG   p.Ser290Leufs\*12   Frameshift     Homozygous

HGVS, Human Genome Variation Society.

The frameshift mutation is located in the carboxy-terminal cysteine knot (CTCK; amino acids 262--354) domain of the WISP3 protein. This domain is highly conserved in vertebrates and involved in the regulation of bone morphogenetic proteins and/or Wnt signaling, and more than one-third of pathogenic mutations of the *WISP3* gene have been reported to occur in this domain ([@ALAWBATHANIMCS002139C2]; [@ALAWBATHANIMCS002139C18]).

We also performed copy-number variant (CNV) calling; however, detected CNVs have not been considered as disease causing for this phenotype ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002139/-/DC1)).

DISCUSSION {#s3}
==========

In developing countries, the focus has been on infectious disease and less attention has been given to rare genetic diseases. In our case, the initial diagnosis was made by the local physicians, classifying the phenotype as a neuromuscular disease because of severe contractures, muscle wasting, and the absence of further biochemical and radiological workup. In contrast, early diagnoses of many PPD cases in the literature were mainly rheumatoid arthritis ([@ALAWBATHANIMCS002139C21]), because they were detected at a less severe stage of the disease progression. We believe that a reduction of life expectancy is not to be expected, even though the disabling course of the disease is dramatic. Notably, the other affected family members of our patient died at ages between 60 and 70 yr.

So far, around 70 families worldwide were confirmed to have PPD by mutation analysis of *WISP3*, which is the only gene known to be associated with PPD ([@ALAWBATHANIMCS002139C2]). Several of these cases were reported in Arab families from Jordan, Saudi Arabia ([@ALAWBATHANIMCS002139C8]), Syria, Lebanon, and Palestine ([@ALAWBATHANIMCS002139C4]), but this is the first PPD case report from Yemen.

The mutation that we found in *WISP3* (c.868_869delAG; p.Ser290Leufs\*12) is a frameshift mutation that leads to a premature termination codon in exon 5 located in the CTCK domain. It had already been reported before in a compound heterozygous status together with a missense mutation in an Italian family ([@ALAWBATHANIMCS002139C7]). Unfortunately, no detailed clinical information was provided on this case in the report; thus, we were not able to compare the clinical phenotypes. The onset of symptoms usually starts between 3 and 6 yr of age and the most common presenting symptoms are progressive multiple joint stiffness, pain, contractures, and eventually gait disturbance. The frequency of PPD is estimated to be about 1 per million in the United Kingdom, but it is likely to be higher in some Arab countries and Turkey ([@ALAWBATHANIMCS002139C25]; [@ALAWBATHANIMCS002139C7]).

No clear genotype--phenotype correlation could be established for *WISP3* mutations until now, and there is a rather small variation in age of onset, severity, and progression. However, it has been shown that patients with nonsense or frameshift mutations do not have a more severe phenotype than those with missense mutations ([@ALAWBATHANIMCS002139C7]; review of 63 cases). Yet, it is challenging to draw a conclusion based on retrospective studies from different countries because of the large differences in the standard of medical care, such as early intervention and rehabilitation that may alter the progression of the disease.

It is very likely that negligence and lack of proper management, such as physical therapy and treatment with NSAIDs, led to the severe outcome of the cases reported here. This study also illustrates that comprehensive gene panel sequencing, such as the Mendeliome analysis, may provide an effective diagnostic tool for deciphering the cause of an unclear presentation of a disease with a strong genetic background and allow timely treatment for the well-being of patients.

METHODS {#s4}
=======

DNA was extracted from blood with standard protocols. About 50 ng of patient 2 ([Fig. 2](#ALAWBATHANIMCS002139F2){ref-type="fig"}) DNA was enriched in a pool of three samples using the TruSight One (Illumina Inc.) according to manufacturer\'s instructions and a 2× 150-bp read length, followed by next-generation sequencing on a MiSeq sequencer. This resulted in 95.4% of uniquely mapped reads with a mean coverage of 82× and 20× coverage for 94.2% of target sequences (see [Table 2](#ALAWBATHANIMCS002139TB2){ref-type="table"} and [Supplemental Material](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002139/-/DC1)).

###### 

Sequencing coverage

  Enrichment kit              Illumina TruSight One
  --------------------------- -----------------------
  Read length                 151
  Mean Cov                    82
  Cov 2×                      98.8
  Cov 10×                     97.7
  Cov 20×                     94.2
  Cov 30×                     87
  Total reads                 16,198,128
  Unique reads (UR)           13,594,734
  Unique mapped reads (UMR)   12,966,845
  %UR                         83.9
  %UMR                        95.4

The data were analyzed using a data analysis pipeline developed at the Cologne Center for Genomics (CCG) ([@ALAWBATHANIMCS002139C9]). At first, raw sequencing reads were mapped to human genome reference (GRC37) using bwa-aln (version 0.6.2) ([@ALAWBATHANIMCS002139C13]) followed by duplication marking using Picard (version 1.64) (<http://broadinstitute.github.io/picard/>). Thereafter, GATK\'s practice guidelines ([@ALAWBATHANIMCS002139C24]) were followed, in which base quality score recalibration and local indel realignment were performed using GATK (version 1.6.11) ([@ALAWBATHANIMCS002139C15]). After the postalignment improvements, variant calling was performed using GATK\'s unified-genotyper (version 1.6.11) and SAMtools' mpileup (version 0.1.18) ([@ALAWBATHANIMCS002139C14]). The variant lists from both callers were merged and annotated using various public databases: dbSNP ([@ALAWBATHANIMCS002139C20]), 1000 Genomes Project (The 1000 Genomes Project Consortium et al. 2010), Exome Variant Server (EVS <http://evs.gs.washington.edu/EVS/>), HGMD professional database ([@ALAWBATHANIMCS002139C22]), dbVAR and DGVa ([@ALAWBATHANIMCS002139C12]), GERP ([@ALAWBATHANIMCS002139C3]), and Ensembl ([@ALAWBATHANIMCS002139C5]). The functional effect of variants were predicted using PolyPhen ([@ALAWBATHANIMCS002139C1]), SIFT ([@ALAWBATHANIMCS002139C11]), and RVIS ([@ALAWBATHANIMCS002139C17]). All of this downstream analysis has been assembled together with a few scripts developed in-house. Moreover, splice site analysis based on [@ALAWBATHANIMCS002139C26] was performed. At last, the annotated variant list is uploaded to CCG\'s web interface and database varbank (<https://varbank.ccg.uni-koeln.de>).

Variant prioritization and data filtering were conducted using the varbank database and analysis pipeline. We filtered out common variants with allele frequencies of \>1% in the following databases: 1000 Genomes (<http://browser.1000genomes.org>), Exome Variant Server (EVS) (<http://evs.gs.washington.edu/EVS/>), and Exome Aggregation Consortium (ExAC) (<http://exac.broadinstitute.org/>).

Additionally, three widely used CNV callers, ExomeDepth ([@ALAWBATHANIMCS002139C30]), XHMM ([@ALAWBATHANIMCS002139C6]), and CoNIFER ([@ALAWBATHANIMCS002139C10]), were used to obtain highly confident calls based on the consensus between the callers (see [Supplemental Material](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002139/-/DC1); [Supplemental File 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002139/-/DC1) for called CNVs and details about callers).
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Data Deposition and Access {#s5a}
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The pathogenic *WISP3* mutation has been submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000612146.
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